Xilis Collaborated with MD Anderson to Advance Novel Technology and Advances Therapeutic Development
Shots:
- The preclinical research agreement combines Xilis' MicroOrganoSphere platform with MD Anderson's expertise to advance the development of novel cancer therapies & cancer research
- Additionally, the collaboration also enables translational research on patient-derived micro tumors & provides new capabilities, improves the efficiency of developing innovative drugs and cell therapies over current xenograft and organoid models, also advances the development of disease models
- MD Anderson's NK cell therapy program (led by Rezvani) is advancing novel treatments for a variety of cancers using engineered cord blood-derived NK cells
Ref: PRNewswire | Image: Xilis
Related News:- MD Anderson Collaborated with Radiopharm Theranostics to Launch Joint Venture for Novel Radiopharmaceuticals Therapies
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
